UroGen Pharma (FRA:UR8) E10: €-3.66 (As of Mar. 2026)


FRA:UR8 UroGen Pharma Ltd FRA:UR8
61 GF Score
Price €30.97
GF Value €16.96
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is UroGen Pharma E10?

UroGen Pharma FRA:UR8 +4.03% 61 E10 is €-3.66 as of Mar. 2026. GuruFocus rates FRA:UR8 with a GF Score™ of 61/100 and a GF Value™ of €16.96 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

UroGen Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.407. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-3.66 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-01), UroGen Pharma's current stock price is €30.97. UroGen Pharma's E10 for the quarter that ended in Mar. 2026 was €-3.66. UroGen Pharma's Shiller PE Ratio of today is .


UroGen Pharma  (FRA:UR8) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


UroGen Pharma E10 Related Terms


UroGen Pharma E10 Historical Data

* Premium members only.

The historical data trend for UroGen Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UroGen Pharma E10 Chart

UroGen Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -3.71

UroGen Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -3.71 -3.66

FRA:UR8 vs SEPN, FTRE, MLTX: E10 Comparison

For the Biotechnology subindustry, UroGen Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


UroGen Pharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, UroGen Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where UroGen Pharma's Shiller PE Ratio falls into.


FRA:UR8
61GF Score
UroGen Pharma Ltd FRA:UR8
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UroGen Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, UroGen Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.407/330.2130*330.2130
=-0.407

Current CPI (Mar. 2026) = 330.2130.

UroGen Pharma Quarterly Data

per share eps CPI Adj_EPS
201606 -0.292 241.018 -0.400
201609 -0.640 241.428 -0.875
201612 0.974 241.432 1.332
201703 -0.343 243.801 -0.465
201706 -0.623 244.955 -0.840
201709 -0.017 246.819 -0.023
201712 -0.625 246.524 -0.837
201803 -0.714 249.554 -0.945
201806 -0.976 251.989 -1.279
201809 -1.097 252.439 -1.435
201812 -1.283 251.233 -1.686
201903 -0.982 254.202 -1.276
201906 -0.956 256.143 -1.232
201909 -0.962 256.759 -1.237
201912 -1.683 256.974 -2.163
202003 -1.620 258.115 -2.073
202006 -1.279 257.797 -1.638
202009 -1.112 260.280 -1.411
202012 -1.134 260.474 -1.438
202103 -0.983 264.877 -1.225
202106 -0.971 271.696 -1.180
202109 -1.148 274.310 -1.382
202112 -1.124 278.802 -1.331
202203 -1.135 287.504 -1.304
202206 -1.116 296.311 -1.244
202209 -1.141 296.808 -1.269
202212 -1.152 296.797 -1.282
202303 -1.214 301.836 -1.328
202306 -0.951 305.109 -1.029
202309 -0.637 307.789 -0.683
202312 -0.605 306.746 -0.651
202403 -0.800 312.332 -0.846
202406 -0.762 314.175 -0.801
202409 -0.460 315.301 -0.482
202412 -0.764 315.605 -0.799
202503 -0.851 319.799 -0.879
202506 -0.910 322.561 -0.932
202509 -0.588 324.800 -0.598
202512 -0.461 324.054 -0.470
202603 -0.407 330.213 -0.407

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-3.66 mean?
UroGen Pharma (FRA:UR8) has a E10 of €-3.66 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on UroGen Pharma and its competitors.
Is UroGen Pharma's E10 too high?
UroGen Pharma's current E10 is €-3.66. Overall, UroGen Pharma has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UroGen Pharma's E10 compare to SEPN and FTRE?
UroGen Pharma's E10 of €-3.66 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on UroGen Pharma and its competitors. UroGen Pharma's current E10 is €-3.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UroGen Pharma stock overvalued right now?
Based on GuruFocus' analysis, UroGen Pharma (FRA:UR8) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.96, compared to a current price of €30.97 — trading 82.6% above its estimated fair value. The current E10 is €-3.66. UroGen Pharma's overall GF Score™ is 61/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For UroGen Pharma (FRA:UR8), the current E10 is €-3.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UroGen Pharma (FRA:UR8) Overvalued in 2026?

Based on GuruFocus' analysis, UroGen Pharma stock appears to be overvalued. The current stock price of €30.97 is trading 82.6% above its estimated GF Value™ of €16.96. GuruFocus considers UroGen Pharma to be Significantly Overvalued.

Key valuation signals for FRA:UR8:

  • E10: €-3.66
  • GF Value™: €16.96 vs. price of €30.97 (82.6% above fair value)
  • GF Score™: 61/100 with 10 warning signs

No single metric tells the full story. See the FRA:UR8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


UroGen Pharma Business Description

Other Exchanges URGN:USA0XOD:UK
Address 400 Alexander Park Drive, 4th Floor, Princeton, NJ, USA, 08540
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.
61GF Score

Get the complete analysis for FRA:UR8

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€30.97
Price
€16.96
GF Value